David Hal­lal bags an­oth­er whop­per round, look­ing to re­cruit more cell and gene ther­a­py up­starts to El­e­vate­Bio Base­Camp

Less than a year af­ter at­tract­ing a launch round of $150 mil­lion, ex-Alex­ion chief David Hal­lal isn’t break­ing stride — yet — for a pan­dem­ic. His start­up cell and gene ther­a­py play­er El­e­vate­Bio in Waltham, MA has at­tract­ed an­oth­er whop­per round, with am­bi­tious plans to build up its port­fo­lio of up­starts.

The lat­est round in­cludes a bevy of new in­vestors: The In­vus Group, Sur­vey­or Cap­i­tal, ED­BI, and Ver­tex Ven­tures — backed by Temasek. They’re sign­ing up along­side ex­ist­ing in­vestors, in­clud­ing F2 Ven­tures, MPM Cap­i­tal, EcoR1 Cap­i­tal, Red­mile Group, and Sam­sara Bio­Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER